Beam Therapeutics Reports Progress Across Ex Vivo and In
First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022 BEAM-301...
Source: globenewswire.com
📰 First Subject Anticipated News
First Subject Anticipated News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from First Subject Anticipated. Real-time updates on events, politics, business and more.
Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones - Press Release
First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022 BEAM
Fourth Development Company To Present Pipeline Nomination Of Two Additional Development Candidates First Subject Anticipated Sickle Cell Disease Second Half
Source: wiredprnews.com